FI114792B - Förfarande för framställning av terapeutiskt aktiva N-fenylalkyl-substituerade alfa-aminokarboxamid-derivat - Google Patents

Förfarande för framställning av terapeutiskt aktiva N-fenylalkyl-substituerade alfa-aminokarboxamid-derivat Download PDF

Info

Publication number
FI114792B
FI114792B FI910354A FI910354A FI114792B FI 114792 B FI114792 B FI 114792B FI 910354 A FI910354 A FI 910354A FI 910354 A FI910354 A FI 910354A FI 114792 B FI114792 B FI 114792B
Authority
FI
Finland
Prior art keywords
formula
oxybenzyl
amino
compound
aminopropionamide
Prior art date
Application number
FI910354A
Other languages
English (en)
Finnish (fi)
Other versions
FI910354A0 (fi
Inventor
Philippe Dostert
Romeo Roncucci
Mario Varasi
Paolo Pevarello
Alberto Bonsignori
Franco Heidempergher
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898912071A external-priority patent/GB8912071D0/en
Priority claimed from GB909007567A external-priority patent/GB9007567D0/en
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of FI910354A0 publication Critical patent/FI910354A0/fi
Application granted granted Critical
Publication of FI114792B publication Critical patent/FI114792B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/02—Monothiocarboxylic acids
    • C07C327/04—Monothiocarboxylic acids having carbon atoms of thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/06—Monothiocarboxylic acids having carbon atoms of thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)

Claims (2)

1. Förfarande för framställning av en terapeutiskt aktiv N-fenylalkyl-substituerad oi-aminokarboxamid med formeln 5 (Ia) ?·?" ,, . i^Y'CH2-N-?-C0^Rl2 (la> Rt—Z-f- Γ R'io 10 eller dess farmaceutiskt godtagbara sait, i vilken formel R7 är furyl, tienyl eller pyridyl eller fenyl, som är osubstituerad’eller substituerad med halogen, Ci-C4-alkyl, is Ci-C4-alkoxi eller CF3, Z är - (CH2) - eller -(CH2)v-Y-f väri v är ett heltal 1-4, och Y är -0-, -S- eller -NH-, R9 är väte eller en Ci-C4-alkyl, Ri0 är väte eller en Ci-C4-alky-1, som är osubstituerad eller substituerad med hydroxi eller fenyl, R'i0 är väte eller Rio och R'i0 bildar till-20 sammans med en intill belägen kolatom en C3-C6-cykloalkyl-ring, och Rn och Ri2 betecknar oberoende av varandra väte eller en Ci-C4-alkyl, och väri j* a) när Z är en grupp -(CH2)V-Y-, väri symbolerna v och Y ; | betecknar detsamma som ovan, och Rio samtidigt är väte el- 25 ler en Ci-C4-alkyl, R'i0 är väte och symbolerna R7 och R9 -— betecknar detsamma som ovan, ätminstone en av resterna Ru och Ri2 är nägot annat än väte, och väri b) när Z är -CH2- *·. och R9 och R'io samtidigt betecknar väte och resterna R7, * · Ru och Ri2 betecknar detsamma som ovan, är Ri0 nägot annat . 30 än väte eller en osubstituerad Ci-C4-alkyl, eller en ';;j terapeutiskt aktiv N-fenylalkyl-substituerad a- ·;·* aminokarboxamid med formeln (Ib) ' · ?H3 ,H aCH2—NH—GH—CON^ ( !b ) H ... eller dess farmaceutiskt godtagbara sait, i vilken fornjel 36 1U7*2 R'7 är en fenylring, som är osubstituerad eller substi-tuerad med en halogenatom, Z' är -(CH2) - eller en grupp -(CH2)V-Y-, väri v är ett heltal 1-4 och Y är -0-, -S-eller -NH-, kännetecknat därav, att 5 (i) för framställning av en förening med formeln (Ia) a) en förening med formeln (Ha) 1C R7_ZO^ ° (m) väri resterna R7 och Z betecknar detsamma som ovan, om-sättes med en förening med formeln (IVa) 15 ^10 R„ mi-c-ct»' (iva) R· 'R’2 n 10 20 väri resterna R9/ Rio» R'io, Rn och Ri2 betecknar detsamma som ovan och Rn och Ri2 inte bäda betecknar en Ci-C4-alkylgrupp, i närvaro av ett reduktionsmedel varvid man erhäller en förening med formeln (Ia) , väri Rn och Ri2 ; · inte bäda betecknar en Ci-C4-alkyl grupp, eller * : 25 b) en förening med formeln (Va) R9 ·. N~C—COOH . (Va) r7—z-j- R‘10 · 30 *;' eller dess alkylester, väri symbolerna R7/ Z, R9, Rio och R'10 betecknar detsamma som ovan, omsättes med en amin med ;··· formeln (Via) 35 ^R11 HNC^ (Via) 1 Rl2 37 114 792 väri resterna Rn och R12 betecknar detsamma som ovan, eller c) en förening med formeln (Vila) 5 ^9 /\.CH2—NH RT-Z-fjf (Vlla^ io väri symbolerna R7, Z, och R9 betecknar detsamma som ovan, omsättes med en förening med formeln (Villa) is w— ch2—CON^ (Villa) R-12 väri W betecknar en halogenatom och resterna Rn och Ri2 betecknar detsamma som ovan, varvid man erhäller en före-20 ning med formeln (Ia), väri R10 och R'i0 bäda betecknar väte, eller d) en förening med formeln (IXa) 1 * » · • · H Rio ; 25 II ^1-, IN-C—<CONv (IXa) r,-z^T r’.= r’2 . 30 väri symbolerna R7, Z, Rio, R'io, Rii och Ri2 betecknar * * » * "il detsamma som ovan, omsättes med en förening med formeln » » '·;·* (Xa) eller (Xla) * * * » * * t ·:··: R"9-W (Xa) R" 'g-CHO (Xla) 35 i fall av föreningen med formeln (Xla) i närvaro av ett v reduktionsmedel, i vilka formler W är en halogenatom, R"9 är en Ci-C4-alkyl och R"'9 betecknar väte eller en 33 1 1 4792 Ci-C3-alkyl, varvid man erhäller en förening med formeln (Ia), väri R9 är en Cx-C.t-alkyl, och (ii) för framställning av en förening med formeln (Ib) a) en förening med formeln (Hb) 5 10 väri resterna R'7 och Z' betecknar detsamma som ovan, omsättes med en förening med formeln (IVb) ch3 h 15 nh2—OH—CON^ (IVb) H i närvaro av ett reduktionsmedel, eller b) en förening med formeln (Vb) 20 H CH3 :. Il : N-CH-COOH . ( Vb ) K , k » ~11 “· * » » * *·. eller dess alkylester, väri symbolerna R'7 och Z' beteck nar detsamma som ovan, omsättes med en förening med for-30 meln (VIb) *: HN^ (VIb) ',35 i och om sä önskas, omvandlas föreningen med formeln (Ia) eller (Ib) tili nägon annan förening med formeln (Ia) eller respektive (Ib) och/eller om sä önskas, omvandlag 39 1 1 47 92 föreningen med formeln (Ia) eller (Ib) tili ett farmaceutiskt godtagbart sait och/eller, om sä önskas, omvandlas ett salt tili en fri förening och/eller, om sä önskas, skiljes en isomerblandning av föreningar med s formeln (Ia) eller (Ib) i enskilda isomerer.
2. Förfarande enligt patentkrav 1, kännetecknat därav, att man framställer en N-fenylalkyl-substituerad a-aminokarboxamid, som är ίο 2-[4-(3-klorbensyl)oxibensyl]aminopropionamid, 2-(4-bensyloxibensyl)amino-3-hydroxi-N-metylpropionamid, 2- [4-(3-klorbensyl)oxibensyl]amino-3-hydroxi-N-metylpro-pionamid, 2-[4-(2-klorbensyl)oxibensyl]amino-3-hydroxi-N-metylpro-15 pionamid, 2-(4-bensyloxibensyl)aminopropionamid, 2-[4-(2-fluorbensyl)oxibensyl]amino-3-hydroxi-N-metylpro-pionamid, 2-[4-(3-fluorbensyl)oxibensyl]amino-3-hydroxi-N-metylpro-20 pionamid, 2-[4-(2-klorbensyl)oxibensyl]aminopropionamid, 2-(4-bensylbensyl)aminopropionamid, ,2- [4- (3-f luorbensyl) oxibensyl] aminopropionamid, •, j j 2-(4-bensylaminobensyl)aminopropionamid, : 1 : 25 2 -[N-(4-bensylbensyl)-N-metyl]aminopropionamid, — 2 -[4 -(3-fenylpropyl)oxibensyl]aminopropionamid, 2- [4- (2-pyridyl)metyloxibensyl] aminopropionamid, 2-[4-(2-tenyl)oxibensyl]aminopropionamid, 2-[4-(2-furfuryl)oxibensyl]aminopropionamid, 30 2-[4-(3-tenyl)oxibensyl]aminopropionamid, 2- [4-(3-furfuryl)oxibensyl]aminopropionamid, 2-(4-bensyltiobensyl) aminopropionamid, ; 1-[(4-bensyloxibensyl)amino]cyklopropan-l-karboxamid, ,·; 1- [ (4-bensyloxibensyl) amino] cyklopentan-l-karboxamid, 35 1-[(4-bensyloxibensyl)amino]cyklopropan-1-N-metylkarbox- amid, ·'* 1- [ (4-bensyloxibensyl) amino] cyklopentan-l-N-metylkar- boxamid, / 40 1 1 4792 [4-(3-klorbensyl)oxibensyl]amino-N,N-dimetylacetamid, 2- [4- (3-trif luormetylbensyl) oxibensyl] amino-3-hydroxi-lime tylpropionamid, 2-[4-(3-metoxibensyl)oxibensyl]amino-3-hydroxi-N-metyl-5 propionamid, 2-[4-(2-trifluormetylbensyl)oxibensyl]amino-3-hydroxi-N-metylpropionamid, 2-[4-(2-metylbensyl)oxibensyl]amino-3-hydroxi-N-metylpro-pionamid, eller 10 2-[4-(3-metylbensyl)oxibensyl]amino-3-hydroxi-N-metylpro- pionamid, bereonde pä omständigheterna antingen som enskilda (S)-eller (R)-isomerer eller som en racemisk blandning av dessa, is eller ett farmaceutiskt godtagbart salt av dessa. * : I « I i t I » I • < I ’ > k ft· · • · ♦ « t · • · » I I . * » · • t ' I ' • k ' t · ’ ► i
FI910354A 1989-05-25 1991-01-23 Förfarande för framställning av terapeutiskt aktiva N-fenylalkyl-substituerade alfa-aminokarboxamid-derivat FI114792B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB898912071A GB8912071D0 (en) 1989-05-25 1989-05-25 N-phenylalkyl substituted-alpha-amino carboxamide derivatives and process for their preparation
GB8912071 1989-05-25
GB9007567 1990-04-04
GB909007567A GB9007567D0 (en) 1990-04-04 1990-04-04 New n-substituted alpha-amino carboxamide derivatives and process for their preparation
PCT/EP1990/000841 WO1990014334A1 (en) 1989-05-25 1990-05-25 N-PHENYLALKYL SUBSTITUTED α-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
EP9000841 1990-05-25

Publications (2)

Publication Number Publication Date
FI910354A0 FI910354A0 (fi) 1991-01-23
FI114792B true FI114792B (sv) 2004-12-31

Family

ID=26295400

Family Applications (1)

Application Number Title Priority Date Filing Date
FI910354A FI114792B (sv) 1989-05-25 1991-01-23 Förfarande för framställning av terapeutiskt aktiva N-fenylalkyl-substituerade alfa-aminokarboxamid-derivat

Country Status (23)

Country Link
US (3) US5236957A (sv)
EP (2) EP0400495B1 (sv)
JP (1) JP2771328B2 (sv)
KR (1) KR0179661B1 (sv)
CN (1) CN1027588C (sv)
AT (1) ATE96775T1 (sv)
AU (1) AU645752B2 (sv)
CA (1) CA2033190C (sv)
CZ (1) CZ281420B6 (sv)
DE (1) DE69004337T2 (sv)
DK (1) DK0400495T3 (sv)
ES (1) ES2062174T3 (sv)
FI (1) FI114792B (sv)
HU (2) HUT55348A (sv)
IE (1) IE63934B1 (sv)
IL (1) IL94466A (sv)
MY (1) MY105618A (sv)
NO (1) NO179944C (sv)
NZ (1) NZ233785A (sv)
PT (1) PT94160B (sv)
RU (1) RU2097371C1 (sv)
WO (1) WO1990014334A1 (sv)
YU (1) YU48322B (sv)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
GB9306899D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
WO1995006630A1 (en) * 1993-08-30 1995-03-09 Otsuka Pharmaceutical Co., Ltd. Benzylamine derivatives
SE9303274D0 (sv) * 1993-10-07 1993-10-07 Astra Ab Novel phenylethyl and phenylproplamines
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
IT1283489B1 (it) * 1996-07-23 1998-04-21 Chiesi Farma Spa Ammidi di alfa-amminoacidi,loro preparazione e loro impiego terapeutico
FR2753967B1 (fr) * 1996-09-27 1998-11-27 Sod Conseils Rech Applic Nouveaux derives de la phenoxyethylamine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
WO1998047869A1 (en) * 1997-04-22 1998-10-29 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
AU4894697A (en) * 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
ES2402104T3 (es) 1997-11-21 2013-04-29 Purdue Neuroscience Company Uso de 2-aminoacetamidas sustituidas para el tratamiento o alivio de la ansiedad
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
CA2370030C (en) * 1999-04-09 2007-08-14 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
DE10049822B4 (de) * 1999-11-03 2005-12-22 Siemens Ag Verfahren zur Darstellung eines Untersuchungsobjektes unter Verwendung von Schnittbildern
US6306911B1 (en) * 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
DK1423168T3 (da) 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
US6667327B2 (en) * 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
AU2003298762A1 (en) * 2002-11-26 2004-06-18 Hercules Incorporated Soluble, associative carboxymethylcellulose, method of making, and uses thereof
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US20040213842A1 (en) * 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US6979750B1 (en) 2003-04-18 2005-12-27 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
ATE411027T1 (de) 2003-10-23 2008-10-15 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
EP1533295A1 (en) * 2003-11-24 2005-05-25 Newron Pharmaceuticals S.p.A. Cyclopentyl Derivatives
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
WO2006001463A1 (ja) 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Ｓ１ｐ受容体結合能を有する化合物およびその用途
ES2319213T3 (es) * 2004-06-23 2009-05-05 F. Hoffmann-La Roche Ag Inhibidores de mao-b.
US20080096965A1 (en) * 2004-09-10 2008-04-24 Newron Pharmaceuticals S.P.A. (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
BRPI0620239B8 (pt) * 2005-12-22 2021-05-25 Newron Pharm Spa derivados de 2-feniletilamino.
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
EA017123B1 (ru) * 2006-06-19 2012-10-30 Ньюрон Фармасьютикалс С.П.А. Способ получения 2-[4-(3- и 2-фторбензилокси)бензиламино]пропанамидов
EP2046451A1 (en) * 2006-07-28 2009-04-15 Alcon Research, Ltd. Monoamine oxidase inhibitors useful for treating disorders of the outer retina
KR100868353B1 (ko) * 2007-03-08 2008-11-12 한국화학연구원 도파민 ｄ4 수용체 길항제인 신규 피페라지닐프로필피라졸유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
JP5440496B2 (ja) 2007-06-15 2014-03-12 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 置換２−［２−（フェニル）エチルアミノ］アルカンアミド誘導体ならびにナトリウムおよび／またはカルシウムチャネル調節剤としてのこれらの使用
MX2010006278A (es) * 2007-12-11 2010-08-31 Newron Pharm Spa Proceso para produccion de 2-[4-(3- o 2-fluorobenciloxi)bencilamin o]propanamidas con un alto grado de pureza.
JP5736175B2 (ja) 2007-12-19 2015-06-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 精神障害の治療に有用なα−アミノアミド誘導体
US9212155B2 (en) * 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
US9206143B2 (en) 2008-03-19 2015-12-08 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
EP2563355B1 (en) 2010-04-27 2016-06-08 Newron Pharmaceuticals S.p.A. Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers
JP6446131B2 (ja) 2014-10-02 2018-12-26 メガバイオウッド カンパニー，リミテッド α−アミノアミド誘導体化合物及びこれを含む薬学的組成物
KR101679568B1 (ko) 2014-10-02 2016-11-28 한국과학기술연구원 알파-아미노아미드 유도체 화합물 및 이를 포함하는 약학적 조성물
EP3237379B1 (en) 2014-12-23 2022-04-06 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
WO2019071162A2 (en) 2017-10-05 2019-04-11 Biogen Inc. PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES
CA3092747A1 (en) 2018-03-08 2019-09-12 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
CN112041296B (zh) * 2018-04-28 2023-12-29 上海璃道医药科技有限公司 包含苯并含氧脂肪环结构的氨基乙酰胺类化合物及其用途
CN108997163A (zh) * 2018-07-18 2018-12-14 华东理工大学 含苯并脂肪环结构的氨基乙酰胺类化合物及其用途
US11111208B2 (en) 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
EP3772510B1 (en) 2019-08-06 2024-02-14 Medichem, S.A. Process for preparing safinamide
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) * 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
US4311853A (en) * 1979-02-06 1982-01-19 The Radiochemical Centre Limited Selenium derivatives of thyroxine and tri-iodothyronine
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
US4267354A (en) * 1979-04-25 1981-05-12 E. R. Squibb & Sons, Inc. Substituted amides having antiinflammatory activity and intermediates
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
GB8409015D0 (en) * 1984-04-06 1984-05-16 Eschem Ltd Binding
DE3416693A1 (de) * 1984-05-05 1985-11-07 Bayer Ag, 5090 Leverkusen Verfahren zur behandlung von cellulosischen fasermaterialien
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4725619A (en) * 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4715619A (en) * 1986-01-13 1987-12-29 Printmark, Inc. Book jacket
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives

Also Published As

Publication number Publication date
US5391577A (en) 1995-02-21
MY105618A (en) 1994-11-30
DE69004337T2 (de) 1994-02-24
EP0400495A1 (en) 1990-12-05
IL94466A (en) 1995-01-24
PT94160A (pt) 1991-01-08
HUT55348A (en) 1991-05-28
NO910270D0 (no) 1991-01-23
HU905133D0 (en) 1991-04-29
NZ233785A (en) 1992-12-23
RU2097371C1 (ru) 1997-11-27
US5236957A (en) 1993-08-17
KR920701131A (ko) 1992-08-11
IE63934B1 (en) 1995-06-28
AU5729990A (en) 1990-12-18
CA2033190C (en) 2003-04-08
FI910354A0 (fi) 1991-01-23
PT94160B (pt) 1997-04-30
WO1990014334A1 (en) 1990-11-29
EP0400495B1 (en) 1993-11-03
DK0400495T3 (da) 1993-12-06
DE69004337D1 (de) 1993-12-09
ES2062174T3 (es) 1994-12-16
CZ252090A3 (en) 1996-06-12
JP2771328B2 (ja) 1998-07-02
ATE96775T1 (de) 1993-11-15
US5502079A (en) 1996-03-26
IL94466A0 (en) 1991-03-10
CN1027588C (zh) 1995-02-08
NO179944B (no) 1996-10-07
EP0426816A1 (en) 1991-05-15
NO179944C (no) 1997-01-15
CA2033190A1 (en) 1990-11-26
CZ281420B6 (cs) 1996-09-11
YU102290A (sh) 1992-07-20
KR0179661B1 (ko) 1999-05-15
IE901878L (en) 1990-11-25
CN1047496A (zh) 1990-12-05
NO910270L (no) 1991-01-23
JPH04500215A (ja) 1992-01-16
AU645752B2 (en) 1994-01-27
HU211550A9 (en) 1995-12-28
YU48322B (sh) 1998-05-15

Similar Documents

Publication Publication Date Title
FI114792B (sv) Förfarande för framställning av terapeutiskt aktiva N-fenylalkyl-substituerade alfa-aminokarboxamid-derivat
FR2896798A1 (fr) Derives de sulfonamides, leur preparation et leur application en therapeutique
JP2000500732A (ja) ２−（４−置換）−ベンジルアミノ−２−メチル−プロパンアミド誘導体
US5446066A (en) Substituted (arylalkoxybenzyl)aminopropanamide derivatives and process for their preparation
US5840764A (en) Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
JPH11509848A (ja) Ｎ−（４−置換−ベンジル）−２−アミノラクタム誘導体
JP3542600B2 (ja) 置換（アリールアルキルアミノベンジル）アミノプロピオンアミド誘導体及びその製造方法
RU2272807C2 (ru) Новые производные амидинов, их получение и их использование в качестве лекарственных средств
EP1177169A1 (fr) Derives de 6- [(aryl et heteroaryl) oxy]methyl] n aphtalene-2- carboximidamide, leur preparation et leur application en therapeutique
HK1006453A1 (en) N-phenylalkyl substituted alfa-amino carboxamide derivatives and process for their preparation
HK1006453B (en) N-phenylalkyl substituted alfa-amino carboxamide derivatives and process for their preparation
KR20010033998A (ko) 신경학적 질병 치료용 1,4-디아자시클로헵탄 유도체
FR2717473A1 (fr) Dérivés de cyclopropylacétonitrile, leur préparation et leur application comme médicaments.
FR2663329A1 (fr) Composes aromatiques amines, procede pour leur preparation et compositions pharmaceutiques les contenant.
IE914126A1 (en) Imidazol-2-yl derivatives of substituted bicyclic compounds¹and process for their preparation
FR2688218A1 (fr) Sels d&#39;ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2654100A1 (fr) Arylalkylenediamines, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPWO2000023437A1 (ja) 含窒素縮合複素環誘導体、その製造法および剤

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: PHARMACIA & UPJOHN S,P.A.